- Home
- Equities - Stocks - Shares
- Company Press Releases
- Arctic Bioscience - Mandatory Notification of Trade
Arctic Bioscience - Mandatory notification of trade
18 Oct 2024 11:41 CEST
Issuer
Arctic Bioscience AS
Siglar AS, a legal person closely associated with a person discharging
managerial responsibility in Arctic Bioscience, has today bought 20,000 shares
in Arctic Bioscience at an average price of NOK 2,32 per share. Following the
transaction, Siglar AS holds 20,000 shares in Arctic Bioscience. In addition,
Siglar AS holds 50% ownership of Capra Invest AS, which holds 1,544,450 in
Arctic Bioscience.
Chairman of the Board at Arctic Bioscience, Harald Nordal, is the owner of
Siglar AS.
Please refer to the attached notification of trading for further details.
This information is subject to the disclosure requirements pursuant to
Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act
§ 5-12.
For more information, please contact:
Jone R. Slinning
CFO
Phone: +47 948 75 469
E-mail: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.
More information:
Access the news on Oslo Bors NewsWeb site
629883_20241018_Appendix_3_Notifying_Transactions_Siglar_AS.pdf
Source
Arctic Bioscience AS
Provider
Oslo Børs Newspoint
Company Name
ARCTIC BIOSCIENCE AS
ISIN
NO0010859580
Symbol
ABS
Market
Euronext Growth